| Product NDC: | 10019-957 | 
| Proprietary Name: | Cyclophosphamide | 
| Non Proprietary Name: | cyclophosphamide | 
| Active Ingredient(s): | 2 g/100mL & nbsp; cyclophosphamide | 
| Administration Route(s): | INTRAVENOUS; ORAL | 
| Dosage Form(s): | INJECTION, POWDER, FOR SOLUTION | 
| Coding System: | National Drug Codes(NDC) | 
| Product NDC: | 10019-957 | 
| Labeler Name: | Baxter Healthcare Corporation | 
| Product Type: | HUMAN PRESCRIPTION DRUG | 
| FDA Application Number: | ANDA040745 | 
| Marketing Category: | ANDA | 
| Start Marketing Date: | 20080521 | 
| Package NDC: | 10019-957-01 | 
| Package Description: | 1 VIAL, SINGLE-DOSE in 1 CARTON (10019-957-01) > 100 mL in 1 VIAL, SINGLE-DOSE (10019-957-11) | 
| NDC Code | 10019-957-01 | 
| Proprietary Name | Cyclophosphamide | 
| Package Description | 1 VIAL, SINGLE-DOSE in 1 CARTON (10019-957-01) > 100 mL in 1 VIAL, SINGLE-DOSE (10019-957-11) | 
| Product NDC | 10019-957 | 
| Product Type Name | HUMAN PRESCRIPTION DRUG | 
| Non Proprietary Name | cyclophosphamide | 
| Dosage Form Name | INJECTION, POWDER, FOR SOLUTION | 
| Route Name | INTRAVENOUS; ORAL | 
| Start Marketing Date | 20080521 | 
| Marketing Category Name | ANDA | 
| Labeler Name | Baxter Healthcare Corporation | 
| Substance Name | CYCLOPHOSPHAMIDE | 
| Strength Number | 2 | 
| Strength Unit | g/100mL | 
| Pharmaceutical Classes | Alkylating Activity [MoA],Alkylating Drug [EPC] |